Neurotech Appoints Beth Marsh as Chief Commercial Officer
Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTO TM (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421666615/en/
Beth Marsh, Chief Commercial Officer
Beth is an established commercial and strategic business executive with more than two decades of leadership experience and expertise in ophthalmology and retina.
'We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,' said Richard Small, Chief Executive Offer. 'I am confident that Beth's expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.'
'This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,' said Beth. 'Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of ENCELTO. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.'
Beth joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial U.S. launch for SYFOVRE, the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Previously, she served in commercial leadership roles at Shire / Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Beth's earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. She also volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University.
ENCELTO is used to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel); a retinal disease that causes progressive vision loss. Your eye surgeon will assess your vision and review your medical history to determine if ENCELTO is the right treatment for you.
IMPORTANT SAFETY INFORMATION
The outpatient surgical procedure should not be performed if you are currently experiencing an active or suspected eye infection.
You should not receive ENCELTO if you have a known hypersensitivity to Endothelial Serum Free Media (Endo-SFM).
Before receiving ENCELTO, tell your eye surgeon about all your medical conditions, including:
Post-operative care:
Magnetic Resonance (MR) Conditional Information
Potential side effects:
Please be advised that ENCELTO and the surgical insertion has related risks such as, but not limited to, endophthalmitis (eye infection), retinal tear and detachment (retina tears and potentially separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion (the ENCELTO begins to work its way out of the way), suture related issues (such as suture related eye irritation or exposure of sutures), temporary or permanent loss of vision, accelerated cataract formation (clouding of the lens of the eye), and delayed dark adaptation (the ability of the eye to adjust from bright lighting conditions to dark lighting conditions).
If delayed dark adaptation occurs, it is unknown for how long these symptoms will be experienced. Take the following safety precautions:
It is common to experience the following symptoms following ENCELTO surgery:
Call your eye surgeon for medical advice about side effects. You may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088.
Please see full Prescribing Information and Patient Information for ENCELTO.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250421666615/en/
CONTACT: Corporate Contact:
Laurie Ferguson, Chief Communications Officer
Phone: 401-556-8649
Email:[email protected]
KEYWORD: UNITED STATES NORTH AMERICA RHODE ISLAND
INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES NEUROLOGY SURGERY PHARMACEUTICAL OPTICAL BIOTECHNOLOGY
SOURCE: Neurotech Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 04/21/2025 09:20 AM/DISC: 04/21/2025 09:19 AM
http://www.businesswire.com/news/home/20250421666615/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Epoch Times
9 hours ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.
Business Wire
10 hours ago
- Business Wire
CUPE: Liberals reward Air Canada's refusal to bargain fairly by crushing flight attendants' Charter rights
TORONTO--(BUSINESS WIRE)--Air Canada asked the government to crush underpaid flight attendants' Charter rights, and Jobs Minister Patty Hajdu only waited a few hours to deliver. The Liberal government has invoked Section 107 of the Canada Labour Code to end a strike by Air Canada flight attendants fighting to end unpaid work and poverty wages. "The Liberals have talked out of both sides of their mouths. They said the best place for this is at the bargaining table. They refused to correct this historic injustice through legislation," said Wesley Lesosky, President of the Air Canada Component of CUPE. "Now, when we're at the bargaining table with an obstinate employer, the Liberals are violating our Charter rights to take job action and give Air Canada exactly what they want — hours and hours of unpaid labour from underpaid flight attendants, while the company pulls in sky-high profits and extraordinary executive compensation." CUPE came to the table with data-driven and reasonable proposals for a fair cost-of-living wage increase and an end to forced unpaid labour. Air Canada responded by sandbagging the negotiations. The Liberal government is rewarding Air Canada's refusal to negotiate fairly by giving them exactly what they wanted. This sets a terrible precedent. Contrary to the Minister's remarks, this will not ensure labour peace at Air Canada. This will only ensure that the unresolved issues will continue to worsen by kicking them down the road. Nor will it ensure labour peace in this industry — because unpaid work is an unfair practice that pervades nearly the entire airline sector, and will continue to arise in negotiations between flight attendants and other carriers.
